Our study further confirmed these soluble molecules (CD28, CXCL10, TNFRSF9, TNFSF14, CD83, and HVEM) as predictive biomarkers in NSCLC, and might be potential targets to boost immunotherapy in patients. The gene discussed is CD83; the disease is non-small cell lung carcinoma.